Form 4: Hims & Hers Health CFO Oluyemi Okupe Executes Stock Options and Sells Shares Under 10b5-1 Plan

Hims & Hers Health's CFO, Oluyemi Okupe, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 15, 2025, Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc., executed stock options to acquire 5,889 shares and 548 shares of Class A Common Stock at exercise prices of $11.53 and $5.01, respectively.
• Okupe then sold 11,581 shares of Class A Common Stock at a weighted average price of $60.2247, with individual sales prices ranging from $59.82 to $60.72.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on May 31, 2024.
• Following these transactions, Okupe directly owns 113,816 shares of Class A Common Stock and holds options to purchase 457,191 additional shares.
• The stock options vest over a 4-year period, with monthly installments beginning on April 1, 2023, for the options priced at $11.53, and with 25% vesting on the first anniversary of January 24, 2022, and the balance vesting monthly thereafter for the options priced at $5.01.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading plan, mitigating potential negative interpretations. However, any insider selling can create some uncertainty.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by a high-ranking officer could be interpreted negatively by some investors, although the pre-arranged trading plan mitigates this concern.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is less concerning given the 10b5-1 plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares while avoiding accusations of insider trading. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Comparing Okupe's transactions to those of CFOs at similar telehealth companies like Teladoc Health or Amwell would provide context.
• For example, if CFOs at comparable companies are also executing pre-planned stock sales, it would suggest this is a normal course of action.
• Conversely, if other CFOs are primarily holding or increasing their positions, it might raise questions about Okupe's sales, even with the 10b5-1 plan.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the pre-arranged trading plan should alleviate concerns.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, insider trading, stock options, Rule 10b5-1, Hims & Hers Health, Oluyemi Okupe, CFO, stock sale